Beneficial effects observed in AD clinical trials will have to consider the possibility that phenothiazines may benefit cognitive decline in AD not only by disaggregating Tau but by inhibiting Casp6-mediated axonal degeneration. This evidence concerns the gene CASP6 and Alzheimer disease.